Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility

Thomas Lars Andresen (Inventor), Rasmus Irming Jølck (Inventor), Linda Maria Bruun (Inventor)

Research output: Patent

114 Downloads (Pure)

Abstract

Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. Currently, the most frequently used imaging-technique for IGRT is Computed Tomography (CT). However, CT- based target delineation of soft tissue tumors tends to only improve the precision and not the accuracy of treatment due to its relatively low soft tissue resolution. In some tumors ∼40% larger volumes are defined on CT compared to MRI, a technique with submillimeter soft tissue resolution. Therefore, it is advantageous to apply both CT and MRI in planning of soft tissue tumor radiotherapy. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1 :1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable Ti contrast enhancement (T1 ∼900 ms) in the rim over at least 3 weeks with clinically observable resolution. Key words: Fiducial marker, MRI, CT, Image Guided Radiotherapy
Original languageEnglish
IPCA61K47/26; A61K49/00; A61K49/04; A61K49/08; A61K49/10; A61K49/12; A61K49/14; A61K49/18
Patent numberWO2018215595
Filing date29/11/2018
CountryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date24/05/2017
Priority numberSE20170050654
Publication statusPublished - 2019

Cite this

Andresen, T. L., Jølck, R. I., & Bruun, L. M. (2019). IPC No. A61K47/26; A61K49/00; A61K49/04; A61K49/08; A61K49/10; A61K49/12; A61K49/14; A61K49/18. Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility. (Patent No. WO2018215595 ).
Andresen, Thomas Lars (Inventor) ; Jølck, Rasmus Irming (Inventor) ; Bruun, Linda Maria (Inventor). / Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility. IPC No.: A61K47/26; A61K49/00; A61K49/04; A61K49/08; A61K49/10; A61K49/12; A61K49/14; A61K49/18. Patent No.: WO2018215595 . Nov 29, 2018.
@misc{1d1d6f73c3a94021bd9feefec0ebcab7,
title = "Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility",
abstract = "Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. Currently, the most frequently used imaging-technique for IGRT is Computed Tomography (CT). However, CT- based target delineation of soft tissue tumors tends to only improve the precision and not the accuracy of treatment due to its relatively low soft tissue resolution. In some tumors ∼40{\%} larger volumes are defined on CT compared to MRI, a technique with submillimeter soft tissue resolution. Therefore, it is advantageous to apply both CT and MRI in planning of soft tissue tumor radiotherapy. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1 :1 containing 3 mM PLA-DTPA(Gd), 40{\%} triglyceride, 5{\%} propylene carbonate and 10{\%} XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable Ti contrast enhancement (T1 ∼900 ms) in the rim over at least 3 weeks with clinically observable resolution. Key words: Fiducial marker, MRI, CT, Image Guided Radiotherapy",
author = "Andresen, {Thomas Lars} and J{\o}lck, {Rasmus Irming} and Bruun, {Linda Maria}",
year = "2019",
language = "English",
type = "Patent",
note = "WO2018215595 ; A61K47/26; A61K49/00; A61K49/04; A61K49/08; A61K49/10; A61K49/12; A61K49/14; A61K49/18",

}

Andresen, TL, Jølck, RI & Bruun, LM Nov. 29 2018, Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility, Patent No. WO2018215595 , IPC No. A61K47/26; A61K49/00; A61K49/04; A61K49/08; A61K49/10; A61K49/12; A61K49/14; A61K49/18.

Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility. / Andresen, Thomas Lars (Inventor); Jølck, Rasmus Irming (Inventor); Bruun, Linda Maria (Inventor).

IPC No.: A61K47/26; A61K49/00; A61K49/04; A61K49/08; A61K49/10; A61K49/12; A61K49/14; A61K49/18. Patent No.: WO2018215595 . Nov 29, 2018.

Research output: Patent

TY - PAT

T1 - Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility

AU - Andresen, Thomas Lars

AU - Jølck, Rasmus Irming

AU - Bruun, Linda Maria

PY - 2019

Y1 - 2019

N2 - Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. Currently, the most frequently used imaging-technique for IGRT is Computed Tomography (CT). However, CT- based target delineation of soft tissue tumors tends to only improve the precision and not the accuracy of treatment due to its relatively low soft tissue resolution. In some tumors ∼40% larger volumes are defined on CT compared to MRI, a technique with submillimeter soft tissue resolution. Therefore, it is advantageous to apply both CT and MRI in planning of soft tissue tumor radiotherapy. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1 :1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable Ti contrast enhancement (T1 ∼900 ms) in the rim over at least 3 weeks with clinically observable resolution. Key words: Fiducial marker, MRI, CT, Image Guided Radiotherapy

AB - Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. Currently, the most frequently used imaging-technique for IGRT is Computed Tomography (CT). However, CT- based target delineation of soft tissue tumors tends to only improve the precision and not the accuracy of treatment due to its relatively low soft tissue resolution. In some tumors ∼40% larger volumes are defined on CT compared to MRI, a technique with submillimeter soft tissue resolution. Therefore, it is advantageous to apply both CT and MRI in planning of soft tissue tumor radiotherapy. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1 :1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable Ti contrast enhancement (T1 ∼900 ms) in the rim over at least 3 weeks with clinically observable resolution. Key words: Fiducial marker, MRI, CT, Image Guided Radiotherapy

M3 - Patent

M1 - WO2018215595

Y2 - 2018/11/29

ER -

Andresen TL, Jølck RI, Bruun LM, inventors. Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility. A61K47/26; A61K49/00; A61K49/04; A61K49/08; A61K49/10; A61K49/12; A61K49/14; A61K49/18. 2019.